Real-world Application of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Masaaki Yoshikawa, Yuta Goto, Masaomi Tsutsumi et al.
✦ AI-curated · Sources linked
Case in brief
This case series described four patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous efgartigimod. Of three patients with typical CIDP, one had marked improvement, while two had limited benefit and stopped treatment. A patient with motor-predominant CIDP had sustained improvement. Favorable responses tended to occur in patients with motor-dominant symptoms. No serious adverse events were reported; one patient experienced mild fatigue after injection.
What made this case unusual
Responses differed among patients with typical CIDP, while the patient with motor-predominant CIDP had sustained improvement; favorable responses tended to accompany motor-dominant symptoms.
Diagnostic / clinical pearl
Clinical response to subcutaneous efgartigimod varied in this small series, including among patients with typical CIDP; motor-dominant symptoms were associated with favorable responses.
Why it matters
Larger studies are needed to identify predictors of response and clarify how disease heterogeneity relates to efgartigimod outcomes.